Butyrophilins Role in Colon Cancer
ConditionColonic Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Paoli-Calmettes
About this trial
quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient is older than 18 years old,
Signed participation consent,
Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting.
Performance Status (PS) 0 or 1
Disqualifiers
Rectal cancer, colon cancer recurrence
Emergency of colon cancer Surgery
History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)
Patient who received neoadjuvant therapy other than chemotherapy
Trial design
Design model
Parallel
Treatments tested in this trial
analysis of BTN and BTNL status
Biological/Vaccineanalysis of BTN and BTNL expression in colon cancer and hepatic metastasis
Treatment groups
200 Participants
are divided into 2 treatment groupsGroup A: non-metastatic colon cancerExperimental treatment 1 intervention
Group B: metastatic colon cancerExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry
healthy and cancerous colon ad metastasis (if applicable) will be analysed by
Time frame
8 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov